|Bid||33.88 x 800|
|Ask||34.00 x 1000|
|Day's Range||32.17 - 34.47|
|52 Week Range||29.50 - 141.01|
|Beta (5Y Monthly)||-1.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||91.43|
The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.
Gilead's cancer ambitions, drug makers continue to mine Covid-19 and potential HIV breakthroughs in a wrap-up of the 40th annual J.P. Morgan Healthcare Conference.
Glaxo (GSK) and Vir are looking to get authorization for the intramuscular administration of their COVID-19 drug candidate, sotrovimab, which is currently authorized for intravenous administration.